Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pediatric Oncology Nutrition Intervention Trial
Sponsor: Corey Hawes
Summary
Nearly 60% of pediatric patients diagnosed with cancer develop malnutrition caused by a combination of disease burden, side effects of chemotherapy, and the intensity of cancer treatment. These patients are known to have an increased risk of infection, treatment-related toxicity, inferior clinical outcomes, and increased risk of mortality. Malnutrition may progress to cancer cachexia, characterized by anorexia, increased inflammation, decreased fat, and decreased muscle mass with subsequent weight loss, which is associated with decreased overall survival. The goal of the proposed research is to determine changes in body composition, weight status, and nutritional status between common nutrition interventions including oral nutrition supplements (ONS), appetite stimulants, and enteral nutrition (EN) among pediatric cancer patients. A secondary goal of this research is to utilize the findings to develop clinical nutrition guidelines for this patient population. The specific objective of the research proposed is to solve the lack of evidence to adequately treat nutritional deficits in the pediatric oncology population. Without this data, there is a lack of clinical consistency in the initiation and selection of appropriate nutrition interventions to provide a more definitive pathway of care. This study can help formulate a clinical guideline for this patient population before, during, and after treatment.
Official title: The Pediatric Oncology Interventional Nutrition Therapy (POINT) Trial: A Pilot Study
Key Details
Gender
All
Age Range
2 Years - 19 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2024-01-31
Completion Date
2025-08-04
Last Updated
2026-10-08
Healthy Volunteers
No
Conditions
Interventions
Oral Nutrition Supplement
8oz (240mL) per dose at least once a day, but up to six times per day depending on estimated nutrient needs. The formula will equate to 1.0kcal/mL
Tube Feed
EN will have a feeding tube placed and started on tube feeds via a designated pump for overnight feeds, meeting at least 50% of estimated energy needs
Cyproheptadine
0.25mg/kg/d divided BID. May titrate by 4mg increments to a max of 12mg/day.
Olanzapine
2.5mg once a day (at night). May titrate by 2.5mg increments to max of 10mg/day
Standard of Care
Diet education on high protein, high calorie food consumption
Locations (1)
University of Kentucky
Lexington, Kentucky, United States